Search results
Understanding CAR T-cell therapy: A conversation with Northside’s Dr. Melhem Solh - Atlanta Business...
The Business Journals· 6 days agoDr. Melhem Solh, medical director of the cellular therapy program at Northside Hospital, answers...
Health Beat: Do the benefits of CAR T-Cell therapy outweigh the risks?
WFMZ Eastern Pennsylvania and Western New Jersey· 5 days agoIn 2017, the FDA approved the first CAR T-cell therapy. Medical experts call it a "breakthrough" and...
India Has Low-Cost CAR T-Cell Therapy: Can US Follow Suit?
Medscape· 4 days agoDr Maurie Markman discusses a news report on decreasing the cost of CAR-T therapy and the potential...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 7 days ago-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 6 days agoIN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies, presented encouraging preliminary ...
UC San Diego Health First in Region to Provide Nov | Newswise
Newswise· 6 days agoThe personalized cellular therapy derived from tumor infiltrating lymphocytes (TIL), is the first...
Adicet Bio gains FDA Fast Track for lupus nephritis treatment By Investing.com
Investing.com· 4 days agoAdministration (FDA) has granted Fast Track Designation to their investigational therapy ADI-001,...
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
Tehachapi News· 6 days agoPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients ...
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study...
The Grass Valley Union· 7 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer ...
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel...
Digital Journal· 6 days agoOverall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysisInterim analysis data reinforces ...